about
Melanoma: from melanocyte to genetic alterations and clinical optionsMicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemiacfDNA analysis from blood in melanomaTailoring the Treatment of Melanoma: Implications for Personalized MedicineCurrent State of Animal (Mouse) Modeling in Melanoma ResearchManaging Side Effects of Vemurafenib Therapy for Advanced MelanomaPathways and therapeutic targets in melanomaPersonalised cancer medicineIntermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case seriesHost kinin B1 receptor plays a protective role against melanoma progression.Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAFEngineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer TherapyEstrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical UtilityA novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent mannerSphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increaseClinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cellsBeyond histology: translating tumor genotypes into clinically effective targeted therapies.Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel.Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer TherapyThe dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.Clinical utility of a blood-based BRAF(V600E) mutation assay in melanomaTyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and ImmunotherapyInhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma modelsPhenotype switching in melanoma: implications for progression and therapy.BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanomaNanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma.Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanomaAdoptive Cell Therapy of Melanoma with Cytokine-induced Killer CellsInhibitor of DNA Binding 4 (ID4) is highly expressed in human melanoma tissues and may function to restrict normal differentiation of melanoma cellsPhosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma.Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatinInhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?
P2860
Q21284811-A2541384-AABD-4472-84B6-7FD2C0BD3892Q26766288-86367360-9530-47AE-AD7F-8EE89104302FQ26772199-B08E4B8C-722E-4FE8-97A3-B6D28EBB68E2Q26775806-5E81D2CD-B70E-4E1C-9B3B-58BFAD7118EEQ26781652-7C2939AE-F34E-4C56-A626-6B82EB1C11A7Q26795510-0CB4C3C8-138E-4D72-82B9-DA06B0DC238EQ26865736-E63252F4-6ADD-4095-AD6A-1FD20B017C9EQ26991908-2A084012-4BDC-450D-BAE4-7AC9E922325CQ27015875-A8E26141-3C16-476B-8E02-8FA277DD3E96Q27340170-4281CCD9-B234-4A1E-BD08-1250A2CB34D0Q27852128-7B92DA5F-4619-422F-8791-849F8C0B1436Q27852827-6BFA4987-FEE7-40AC-8DD7-8E44971B25B9Q27853045-7485A84E-029F-4C36-9231-17E7D5415483Q28073956-16559D21-42D2-4274-8C19-9F4AEA93D61AQ28076097-776BEC4D-C0DA-4672-8731-2F3AABDF3728Q28078465-C4C08EFA-D751-48BB-BD0C-4FDC1906A9C8Q28817145-E59378AF-D98B-4214-872B-BDA46FADBFB1Q28830269-C224C5F0-7636-456A-A355-64C96D27EAB5Q30828178-30BC3DD1-A9EB-4619-BB68-EB9B299EB9B0Q30844792-CE371DA1-50E5-4644-948E-47207E258C0EQ33560928-BDEDEC4F-2CA4-4197-B69B-A41EFBD7C36DQ33667485-D549C0BF-CA06-455D-A53B-939E2BC017B5Q33674041-EA1CD9E4-5D9F-413A-B6BD-C8B62C0E5944Q33859472-08CCD330-F1F1-4E5F-AFD2-1BAF99EDBDCDQ34572036-68915BFD-B6B9-49B4-B7A3-069640FEDA1CQ34646769-63FD20E7-A24C-4CD4-8FBE-B3C1077AF84EQ34662946-5B983B0F-305D-40FE-B531-41D028381950Q34671658-0339DFCC-9C58-4036-9CAD-9939D6CE8870Q34677194-9AF87599-5D89-497A-BEEB-E7319C30A86BQ35081779-097E9BA0-2932-4A56-9A16-B1F2BDD604A7Q35141834-64DFB775-8EFB-4E34-909B-0DB0249FB46FQ35225907-96BA7064-C769-4FA0-9BB7-EFB9C3BCDEF1Q35434352-F1CB5D0C-D943-4EC9-991B-2BD7243FE566Q35543911-597612F1-2D74-48A7-B625-079303294FFAQ35553504-A1EAA28A-B798-4D0F-9733-AE4687CE48D4Q35609071-3EDFFF4B-81B5-42B7-8394-D17A5C805AF8Q35619558-F023A158-D442-4ED7-B97F-1CC9295AE0DCQ35742521-AAD86B74-26BE-422D-93B9-E75FDBBD6979Q35746524-E1812D37-E753-454D-9792-9417F70FD376Q35828512-B33486D9-8DCE-4863-9683-2DCECFA16669
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Resistance to BRAF-targeted therapy in melanoma.
@en
type
label
Resistance to BRAF-targeted therapy in melanoma.
@en
prefLabel
Resistance to BRAF-targeted therapy in melanoma.
@en
P1476
Resistance to BRAF-targeted therapy in melanoma.
@en
P2093
Ryan J Sullivan
P304
P356
10.1016/J.EJCA.2012.11.019
P577
2013-01-02T00:00:00Z